Skip to main content
Erschienen in: Infection 2/2019

19.12.2018 | Brief Report

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam

verfasst von: Ibai Los-Arcos, Oscar Len, María Teresa Martín-Gómez, Juan José González-López, Berta Saéz-Giménez, María Deu, Xavier Nuvials, Ricard Ferrer, Antonio Román, Joan Gavaldà

Erschienen in: Infection | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

We describe two cystic fibrosis patients infected with pandrug-resistant Burkholderia cepacia complex, with the exception of ceftazidime–avibactam, who received prophylaxis with this antibiotic during lung transplantation. Although both patients had a post-operative relapse of respiratory infection, one with positive blood cultures, ceftazidime–avibactam treatment yielded a favourable outcome. 12 months after transplantation, one patient presented an excellent clinical outcome. However, the other patient died 10 months later due to severe B. cepacia sinusitis with intracranial invasion.
Literatur
1.
Zurück zum Zitat Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36:99–110.CrossRefPubMed Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36:99–110.CrossRefPubMed
2.
Zurück zum Zitat Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2:73–82.CrossRefPubMed Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2:73–82.CrossRefPubMed
3.
Zurück zum Zitat Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502–11.CrossRefPubMedPubMedCentral Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502–11.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.CrossRefPubMed Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.CrossRefPubMed
5.
Zurück zum Zitat De Soyza A, Meachery G, Hester KLM, Nicholson A, Parry G, Tocewicz K, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Hear lung Transplant. 2010;29:1395–404.CrossRef De Soyza A, Meachery G, Hester KLM, Nicholson A, Parry G, Tocewicz K, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Hear lung Transplant. 2010;29:1395–404.CrossRef
6.
Zurück zum Zitat van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase combinations. Clin Infect Dis. 2016;63:234–41.CrossRefPubMedPubMedCentral van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase combinations. Clin Infect Dis. 2016;63:234–41.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46:483–93.CrossRefPubMed Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46:483–93.CrossRefPubMed
8.
Zurück zum Zitat Spilker T, Baldwin A, Bumford A, Dowson CG, Mahenthiralingam E, LiPuma JJ. Expanded multilocus sequence typing for Burkholderia species. J Clin Microbiol. 2009;47:2607–10.CrossRefPubMedPubMedCentral Spilker T, Baldwin A, Bumford A, Dowson CG, Mahenthiralingam E, LiPuma JJ. Expanded multilocus sequence typing for Burkholderia species. J Clin Microbiol. 2009;47:2607–10.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic Fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025–30.CrossRefPubMed Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic Fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025–30.CrossRefPubMed
10.
Zurück zum Zitat Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–52.CrossRefPubMedPubMedCentral Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–52.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Nosotti M, Dell’Amore A, Diso D, Oggionni T, Aliberti S, Study Group for Thoracic Organs Transplantation E, et al. Selection of candidates for lung transplantation: the First Italian Consensus Statement. Transplant Proc. 2017;49:702–6.CrossRefPubMed Nosotti M, Dell’Amore A, Diso D, Oggionni T, Aliberti S, Study Group for Thoracic Organs Transplantation E, et al. Selection of candidates for lung transplantation: the First Italian Consensus Statement. Transplant Proc. 2017;49:702–6.CrossRefPubMed
12.
Zurück zum Zitat Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732–7.CrossRefPubMed Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732–7.CrossRefPubMed
13.
Zurück zum Zitat Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.CrossRefPubMed Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.CrossRefPubMed
14.
Zurück zum Zitat Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2009;179:257–8.CrossRefPubMed Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2009;179:257–8.CrossRefPubMed
15.
Zurück zum Zitat Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime–avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95.CrossRefPubMed Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime–avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95.CrossRefPubMed
16.
Zurück zum Zitat Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70:2862–9.CrossRefPubMed Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70:2862–9.CrossRefPubMed
17.
Zurück zum Zitat Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime–avibactam. Antimicrob Agents Chemother. 2018;62:e02213-17.CrossRefPubMedPubMedCentral Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime–avibactam. Antimicrob Agents Chemother. 2018;62:e02213-17.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Barlow G, Morice A. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam. J Antimicrob Chemother. 2018;73:2270–1.CrossRefPubMed Barlow G, Morice A. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam. J Antimicrob Chemother. 2018;73:2270–1.CrossRefPubMed
19.
Zurück zum Zitat Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8.CrossRefPubMedPubMedCentral Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne bla KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097–16.PubMedPubMedCentral Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne bla KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097–16.PubMedPubMedCentral
Metadaten
Titel
Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam
verfasst von
Ibai Los-Arcos
Oscar Len
María Teresa Martín-Gómez
Juan José González-López
Berta Saéz-Giménez
María Deu
Xavier Nuvials
Ricard Ferrer
Antonio Román
Joan Gavaldà
Publikationsdatum
19.12.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 2/2019
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1261-y

Weitere Artikel der Ausgabe 2/2019

Infection 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.